Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Glicentin Rat ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Species:Rat
Please select your region to see available products and prices.
Cat. No. Size Price

RSCYK111R 96 wells (1 kit)
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antibody


Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

30 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.206–50 pmol/ml

Intra-assay (Within-Run)

CV = 4.56 - 7.82

Inter-assay (Run-to-Run)

CV = 3.16 - 7.59

Spiking Recovery

Rat plasma A - 95,72% Rat plasma B - 92,34%


Research topic

Animal studies


Glicentin is a 69-amino-acid peptide containing glucagon and oxyntomodulin sequences in the molecule. It is
suggested that glicentin and oxyntomodulin are produced in the intestinal L-cells and glucagon in A-cells
in the pancreas, these peptides are derived from a common precursor by two different tissue-specific processing
pathways. In 1983, the amino acid sequence of human glicentin was deduced by Bell et al. from the genomic
sequence of human preproglucagon. Glicentin is a major form of gut glucagon-like immunoreactants (Gut GLIs).
In mammalian small intestine, proglucagon is processed into glicentin, oxyntomodulin, and glucagon -like peptide
1(GLP-1) and glucagon -like peptide 2 (GLP-2). GLP-1(7-37) and GLP-1(7-36)amide have been isolated from
the intestine and pancreas. It has been known that the GLP-1 sequence is well conserved between species in all
mammals studied. Using synthetic peptides, several investigators have demonstrated that in contrast to GLP-1 (1-37), truncated GLP-1(7-36)amide and GLP-1(7-37) have several physiological effects. However, the physiological role of glicentin, a major gut glucagon, is still unclear. It has been known that the circulating level of plasma glicentin-like peptides increases significantly nutrient ingestion. Yanaihara institute Inc. has succeeded in developing a specific and convenient EIA kit for determination of rat glicentin in plasma.

References to Product


  • Ishihara, S. et al.: Helicobacter pylori infection accelerates gene expression of glicentin in gastric mucosa. Its association with intestinal metaplasia of the stomach. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 32: 460-464, 1997
  • Ohneda, A. et al.: Effect of glicentin-related peptides on glucagon secretion in anaesthetized dogs. DIABETOLOGIA 29: 397-401, 1986
  • Ohneda, A. et al.: Effect of intraluminal administration of amino acids upon plasma glicentin. DIABETES RESEARCH AND CLINICAL PRACTICE 5: 265-270, 1988
  • Ohneda, A. et al.: Insulinotropic action of human glicentin in dogs. METABOLISM, CLINICAL AND EXPERIMENTAL 44: 47-51, 1995
  • Shibata, C. et al.: Effect of glucagon, glicentin, glucagon-like peptide-1 and -2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 36: 1049-1055, 2001
Related Products Docs